ReviewFrontiers in physiology2015
Patient-Specific Age: The Other Side of the Coin in Advanced Mesenchymal Stem Cell Therapy.
Review in Frontiers in physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The molecular mechanisms of action of PPAR-γ agonists in the treatment of corneal alkali burns (Review).International journal of molecular medicine · 2016Pooled it
- Regenerative and translational medicine in COPD: hype and hope.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Novel hydrogel system eliminates subculturing and improves retention of nonsenescent mesenchymal stem cell populations.Regenerative medicine · 2023Article
- Review
- Review
- Declined adipogenic potential of senescent MSCs due to shift in insulin signaling and altered exosome cargo.Frontiers in cell and developmental biology · 2022Article
- Alterations in cartilage quantification before and after injections of mesenchymal stem cells into osteoarthritic knees.Scientific reports · 2021Article
- Novel cell sources for bone regeneration.MedComm · 2021Review
- Kinship of conditionally immortalized cells derived from fetal bone to human bone-derived mesenchymal stroma cells.Scientific reports · 2021Article
- Effects of recipient age, heparin release and allogeneic bone marrow-derived stromal cells on vascular graft remodeling.Acta biomaterialia · 2021Article
- Identification and characterization of a large source of primary mesenchymal stem cells tightly adhered to bone surfaces of human vertebral body marrow cavities.Cytotherapy · 2020Article
- Mesenchymal Stromal Cells as Critical Contributors to Tissue Regeneration.Frontiers in cell and developmental biology · 2020Review
- Mesenchymal Stem Cell Senescence and Rejuvenation: Current Status and Challenges.Frontiers in cell and developmental biology · 2020Review
- Multi-Parameter Analysis of Biobanked Human Bone Marrow Stromal Cells Shows Little Influence for Donor Age and Mild Comorbidities on Phenotypic and Functional Properties.Frontiers in immunology · 2019Article
- Treatment of osteonecrosis of the femoral head by core decompression and implantation of fully functional ex vivo-expanded bone marrow-derived mesenchymal stem cells: a proof-of-concept study.Stem cells and cloning : advances and applications · 2019Article
- Long-Term Safety and Efficacy of Single or Repeated Intra-Articular Injection of Allogeneic Neonatal Mesenchymal Stromal Cells for Managing Pain and Lameness in Moderate to Severe Canine Osteoarthritis Without Anti-inflammatory Pharmacological Support: Pilot Clinical Study.Frontiers in veterinary science · 2019Article
- Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells.Cytotechnology · 2018Article
- Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy.International journal of molecular sciences · 2017Review
- Fibroblast Growth Factor Type 1 (FGF1)-Overexpressed Adipose-Derived Mesenchaymal Stem Cells (AD-MSCStem cell reviews and reports · 2017Article
- iPS cell technologies and their prospect for bone regeneration and disease modeling: A mini review.Journal of advanced research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multipotential mesenchymal stromal cells (MSC) are present as a rare subpopulation within any type of stroma in the body of higher animals. Prominently, MSC have been recognized to reside in perivascular locations, supposedly maintaining blood vessel integrity. During tissue damage and injury, MSC/pericytes become activated, evade from their perivascular niche and are thus assumed to support wound healing and tissue regeneration. In vitro MSC exhibit demonstrated capabilities to differentiate into a wide variety of tissue cell types. Hence, many MSC-based therapeutic approaches have been performed to address bone, cartilage, or heart regeneration. Furthermore, prominent studies showed efficacy of ex vivo expanded MSC to countervail graft-vs.-host-disease. Therefore, additional fields of application are presently conceived, in which MSC-based therapies potentially unfold beneficial effects, such as amelioration of non-healing conditions after tendon or spinal cord injury, as well as neuropathies. Working along these lines, MSC-based scientific research has been forged ahead to prominently occupy the clinical stage. Aging is to a great deal stochastic by nature bringing forth changes in an individual fashion. Yet, is aging of stem cells or/and their corresponding niche considered a determining factor for outcome and success of clinical therapies?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.